EPS for OptiNose, Inc. (OPTN) Expected At $-0.74 as of June, 12

May 17, 2018 - By Laura Small

On June, 12. Investors wait OptiNose, Inc. (NASDAQ:OPTN) to report its quarterly earnings, Zacks reports. 15.63 % negative EPS growth is what analysts predict. $-0.64 earnings per share was reported for previous quarter. Ticker’s shares touched $24.58 during the last trading session after 4.51% change.OptiNose, Inc. is after having 0.00% since May 17, 2017. OPTN has 597,935 volume or 618.64% up from normal. OPTN underperformed by 11.55% the S&P500.

OptiNose, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of products for patients treated by ear, nose, and throat; and allergy specialists in the United States.The firm is valued at $931.81 million. The company's lead product includes XHANCE, a therapeutic product utilizing its proprietary breath powered exhalation delivery system that delivers a topically-acting and potent anti-inflammatory corticosteroid for the treatment of chronic rhinosinusitis with and without nasal polyps.Currently it has negative earnings. It also markets AVP-825 for the acute treatment of migraines in adults through its license agreement with Avanir Pharmaceuticals, Inc.

For more OptiNose, Inc. (NASDAQ:OPTN) news announced recently go to: Benzinga.com, Nasdaq.com, Nasdaq.com, Seekingalpha.com or Digitaljournal.com. The titles are as follows: “Benzinga’s Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings” announced on May 16, 2018, “Optinose to Report First Quarter 2018 Financial Results and Corporate Updates on May 14, 2018” on May 07, 2018, “Optinose Reports First Quarter 2018 Financial Results and Recent Operational Highlights” with a publish date: May 14, 2018, “OptiNose, Inc. 2018 Q1 – Results – Earnings Call Slides” and the last “OptiNose, Inc. to Host Earnings Call” with publication date: May 14, 2018.

OptiNose, Inc. (NASDAQ:OPTN) Analyst Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.